{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:59:32Z","timestamp":1773320372341,"version":"3.50.1"},"reference-count":217,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Alzheimer\u2019s disease (AD) remains a major challenge in developing effective treatments\ndue to its complex pathophysiology, including the accumulation of amyloid-beta plaques\nand tau tangles. Small interfering RNA (siRNA) technology offers promise for targeted gene\nsilencing, but effective delivery to the central nervous system remains a significant obstacle.\nViral vectors have emerged as potent delivery vehicles for transporting siRNA to neural tissues.\nThis review explores the utilization of viral vectors for siRNA delivery in AD, focusing on delivery\nstrategies and challenges. We discuss the design and optimization of viral vectors, targeting\nstrategies, and safety considerations. Additionally, we examine recent advancements and\nprospects for enhancing viral vector-mediated siRNA delivery in AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113892010334094241112190337","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T02:46:57Z","timestamp":1736822817000},"page":"1-22","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact and Significance of Viral Vectors for siRNA Delivery in the Treatment of Alzheimer\u2019s Disease"],"prefix":"10.2174","volume":"27","author":[{"given":"Chintan","family":"Aundhia","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, AT &amp; Po Piparia, Waghodia, Vadodara, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4614-9797","authenticated-orcid":true,"given":"Ghanshyam","family":"Parmar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, AT &amp; Po Piparia, Waghodia, Vadodara, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4274-0764","authenticated-orcid":true,"given":"Chitrali","family":"Talele","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, AT &amp; Po Piparia, Waghodia, Vadodara, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3975-9062","authenticated-orcid":true,"given":"Rahul","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, AT &amp; Po Piparia, Waghodia, Vadodara, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1512-5952","authenticated-orcid":true,"given":"Mamta","family":"Kumari","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, AT &amp; Po Piparia, Waghodia, Vadodara, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-7096","authenticated-orcid":true,"given":"Jay","family":"Chudasama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, AT &amp; Po Piparia, Waghodia, Vadodara, Gujarat, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clinbiochem.2019.04.015","volume":"72","author":"Zv\u011b\u0159ov\u00e1 M.","year":"2019","unstructured":"Zv\u011b\u0159ov\u00e1 M.; Clinical aspects of Alzheimer\u2019s disease. Clin Biochem  2019,72,3-6","journal-title":"Clin Biochem"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1212\/WNL.65.6_suppl_3.S10","volume":"65","author":"Feldman H.H.","year":"2005","unstructured":"Feldman H.H.; Woodward M.; The staging and assessment of moderate to severe Alzheimer disease. Neurology  2005,65(6_suppl_3)(Suppl. 3),S10-S7","journal-title":"Neurology"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"Sperling R.A.","year":"2011","unstructured":"Sperling R.A.; Aisen P.S.; Beckett L.A.; Bennett D.A.; Craft S.; Fagan A.M.; Iwatsubo T.; Jack C.R.; Kaye J.; Montine T.J.; Park D.C.; Reiman E.M.; Rowe C.C.; Siemers E.; Stern Y.; Yaffe K.; Carrillo M.C.; Thies B.; Morrison-Bogorad M.; Wagster M.V.; Phelps C.H.; Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging\u2010Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement  2011,7(3),280-292","journal-title":"Alzheimers Dement"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000369101","volume":"24","author":"Sadigh-Eteghad S.","year":"2015","unstructured":"Sadigh-Eteghad S.; Sabermarouf B.; Majdi A.; Talebi M.; Farhoudi M.; Mahmoudi J.; Amyloid-beta: a crucial factor in Alzheimer\u2019s disease. Med Princ Pract  2015,24(1),1-10","journal-title":"Med Princ Pract"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3233\/JAD-2009-0960","volume":"16","author":"Huang H.C.","year":"2009","unstructured":"Huang H.C.; Jiang Z.F.; Accumulated amyloid-\u03b2 peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer\u2019s disease. J Alzheimers Dis  2009,16(1),15-27","journal-title":"J Alzheimers Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.3390\/molecules22101692","volume":"22","author":"Penke B.","year":"2017","unstructured":"Penke B.; Bog\u00e1r F.; F\u00fcl\u00f6p L.; \u03b2-Amyloid and the pathomechanisms of Alzheimer\u2019s disease: a comprehensive view. Molecules  2017,22(10),1692","journal-title":"Molecules"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1750-1326-9-48","volume":"9","author":"Tu S.","year":"2014","unstructured":"Tu S.; Okamoto S.; Lipton S.A.; Xu H.; Oligomeric A\u03b2-induced synaptic dysfunction in Alzheimer\u2019s disease. Mol Neurodegener  2014,9(1),48","journal-title":"Mol Neurodegener"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.arr.2014.07.004","volume":"18","author":"Avila-Mu\u00f1oz E.","year":"2014","unstructured":"Avila-Mu\u00f1oz E.; Arias C.; When astrocytes become harmful: Functional and inflammatory responses that contribute to Alzheimer\u2019s disease. Ageing Res Rev  2014,18,29-40","journal-title":"Ageing Res Rev"},{"key":"ref=9","first-page":"1003","volume":"1","author":"Kempuraj D.","year":"2016","unstructured":"Kempuraj D.; Thangavel R.; Natteru P.A.; Selvakumar G.P.; Saeed D.; Zahoor H.; Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine  2016,1(1),1003","journal-title":"J Neurol Neurosurg Spine"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2174\/1567205043332162","volume":"1","author":"Aslan M.","year":"2004","unstructured":"Aslan M.; Ozben T.; Reactive oxygen and nitrogen species in Alzheimer\u2019s disease. Curr Alzheimer Res  2004,1(2),111-119","journal-title":"Curr Alzheimer Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e34929","DOI":"10.1371\/journal.pone.0034929","volume":"7","author":"Cha M.Y.","year":"2012","unstructured":"Cha M.Y.; Han S.H.; Son S.M.; Hong H.S.; Choi Y.J.; Byun J.; Mook-Jung I.; Mitochondria-specific accumulation of amyloid \u03b2 induces mitochondrial dysfunction leading to apoptotic cell death. PLoS One  2012,7(4),e34929","journal-title":"PLoS One"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nm0796-783","volume":"2","author":"Alonso A.C.","year":"1996","unstructured":"Alonso A.C.; Grundke-Iqbal I.; Iqbal K.; Alzheimer\u2019s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med  1996,2(7),783-787","journal-title":"Nat Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0072-9752(07)01222-5","volume":"89","author":"Gomez-Isla T.","year":"2008","unstructured":"Gomez-Isla T.; Spires T.; De Calignon A.; Hyman B.T.; Neuropathology of Alzheimer\u2019s disease. Handb Clin Neurol  2008,89,233-243","journal-title":"Handb Clin Neurol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1146\/annurev.biochem.75.103004.142637","volume":"75","author":"Stokin G.B.","year":"2006","unstructured":"Stokin G.B.; Goldstein L.S.B.; Axonal transport and Alzheimer\u2019s disease. Annu Rev Biochem  2006,75(1),607-627","journal-title":"Annu Rev Biochem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"10145","DOI":"10.3390\/ijms221810145","volume":"22","author":"Siano G.","year":"2021","unstructured":"Siano G.; Falcicchia C.; Origlia N.; Cattaneo A.; Di Primio C.; Non-canonical roles of tau and their contribution to synaptic dysfunction. Int J Mol Sci  2021,22(18),10145","journal-title":"Int J Mol Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3389\/fnins.2019.00659","volume":"13","author":"Chen X.Q.","year":"2019","unstructured":"Chen X.Q.; Mobley W.C.; Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric A\u03b2 and tau species. Front Neurosci  2019,13,659","journal-title":"Front Neurosci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3233\/JAD-160612","volume":"57","author":"Rajmohan R.","year":"2017","unstructured":"Rajmohan R.; Reddy P.H.; Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer\u2019s disease neurons. J Alzheimers Dis  2017,57(4),975-999","journal-title":"J Alzheimers Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"117253","DOI":"10.1016\/j.jns.2020.117253","volume":"421","author":"Bhatia V.","year":"2021","unstructured":"Bhatia V.; Sharma S.; Role of mitochondrial dysfunction, oxidative stress and autophagy in progression of Alzheimer\u2019s disease. J Neurol Sci  2021,421,117253","journal-title":"J Neurol Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"316523","DOI":"10.1155\/2013\/316523","volume":"2013","author":"Zhao Y.","year":"2013","unstructured":"Zhao Y.; Zhao B.; Oxidative stress and the pathogenesis of Alzheimer\u2019s disease. Oxid Med Cell Longev  2013,2013,316523","journal-title":"Oxid Med Cell Longev"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1254\/jphs.CPJ04006X","volume":"97","author":"Takuma K.","year":"2005","unstructured":"Takuma K.; Yan S.S.; Stern D.M.; Yamada K.; Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer\u2019s disease. J Pharmacol Sci  2005,97(3),312-316","journal-title":"J Pharmacol Sci"},{"key":"ref=21","first-page":"1","volume":"16","author":"Cummings J.","year":"2021","unstructured":"Cummings J.; New approaches to symptomatic treatments for Alzheimer\u2019s disease. Mol Neurodegener  2021,16,1-13","journal-title":"Mol Neurodegener"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"114517","DOI":"10.1016\/j.addr.2022.114517","volume":"189","author":"Chen L.","year":"2022","unstructured":"Chen L.; Cruz E.; Oikari L.E.; Padmanabhan P.; Song J.; G\u00f6tz J.; Opportunities and challenges in delivering biologics for Alzheimer\u2019s disease by low-intensity ultrasound. Adv Drug Deliv Rev  2022,189,114517","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/2045-8118-9-23","volume":"9","author":"Luissint A.C.","year":"2012","unstructured":"Luissint A.C.; Artus C.; Glacial F.; Ganeshamoorthy K.; Couraud P.O.; Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS  2012,9(1),23","journal-title":"Fluids Barriers CNS"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/scipharm87010006","volume":"87","author":"Bors L.A.","year":"2019","unstructured":"Bors L.A.; Erd\u0151 F.; Overcoming the blood\u2013brain barrier. challenges and tricks for CNS drug delivery. Sci Pharm  2019,87(1),6","journal-title":"Sci Pharm"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/ijms20020381","volume":"20","author":"Wong K.H.","year":"2019","unstructured":"Wong K.H.; Riaz M.K.; Xie Y.; Zhang X.; Liu Q.; Chen H.; Bian Z.; Chen X.; Lu A.; Yang Z.; Review of current strategies for delivering Alzheimer\u2019s disease drugs across the blood-brain barrier. Int J Mol Sci  2019,20(2),381","journal-title":"Int J Mol Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1002\/anie.200802808","volume":"48","author":"Jakob-Roetne R.","year":"2009","unstructured":"Jakob-Roetne R.; Jacobsen H.; Alzheimer\u2019s disease: from pathology to therapeutic approaches. Angew Chem Int Ed  2009,48(17),3030-3059","journal-title":"Angew Chem Int Ed"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ejpb.2020.01.005","volume":"149","author":"Teixeira M.I.","year":"2020","unstructured":"Teixeira M.I.; Lopes C.M.; Amaral M.H.; Costa P.C.; Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. Eur J Pharm Biopharm  2020,149,192-217","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1021\/acs.molpharmaceut.0c01238","volume":"18","author":"Mendon\u00e7a M.C.P.","year":"2021","unstructured":"Mendon\u00e7a M.C.P.; Kont A.; Aburto M.R.; Cryan J.F.; O\u2019Driscoll C.M.; Advances in the design of (nano) formulations for delivery of antisense oligonucleotides and small interfering RNA: Focus on the central nervous system. Mol Pharm  2021,18(4),1491-1506","journal-title":"Mol Pharm"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"Mitchell M.J.","year":"2021","unstructured":"Mitchell M.J.; Billingsley M.M.; Haley R.M.; Wechsler M.E.; Peppas N.A.; Langer R.; Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov  2021,20(2),101-124","journal-title":"Nat Rev Drug Discov"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/pharmaceutics12121216","volume":"12","author":"Kimura S.","year":"2020","unstructured":"Kimura S.; Harashima H.; Current status and challenges associated with CNS-targeted gene delivery across the BBB. Pharmaceutics  2020,12(12),1216","journal-title":"Pharmaceutics"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/sj.gt.3302719","volume":"13","author":"Hong C-S.","year":"2006","unstructured":"Hong C-S.; Goins W.F.; Goss J.R.; Burton E.A.; Glorioso J.C.; Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer\u2019s disease-related amyloid-\u03b2 peptide in vivo. Gene Ther  2006,13(14),1068-1079","journal-title":"Gene Ther"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12035-018-1068-y","volume":"56","author":"Raikwar S.P.","year":"2019","unstructured":"Raikwar S.P.; Thangavel R.; Dubova I.; Selvakumar G.P.; Ahmed M.E.; Kempuraj D.; Zaheer S.A.; Iyer S.S.; Zaheer A.; Targeted gene editing of glia maturation factor in microglia: a novel Alzheimer\u2019s disease therapeutic target. Mol Neurobiol  2019,56(1),378-393","journal-title":"Mol Neurobiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","volume":"13","author":"Dana H.","year":"2017","unstructured":"Dana H.; Chalbatani G.M.; Mahmoodzadeh H.; Gharagouzlo E.; Karimloo R.; Rezaiean O.; Moradzadeh A.; Mazraeh A.; Marmari V.; Rashno M.M.; Mehmandoost N.; Moazzen F.; Ebrahimi M.; Abadi S.J.; Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci  2017,13(2),48-57","journal-title":"Int J Biomed Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1093\/nar\/gki762","volume":"33","author":"Lin X.","year":"2005","unstructured":"Lin X.; Ruan X.; Anderson M.G.; McDowell J.A.; Kroeger P.E.; Fesik S.W.; Shen Y.; siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res  2005,33(14),4527-4535","journal-title":"Nucleic Acids Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"114968","DOI":"10.1016\/j.addr.2023.114968","volume":"199","author":"Imran Sajid M.","year":"2023","unstructured":"Imran Sajid M.; Sultan Sheikh F.; Anis F.; Nasim N.; Sumbria R.K.; Nauli S.M.; Kumar Tiwari R.; siRNA drug delivery across the blood\u2013brain barrier in Alzheimer\u2019s disease. Adv Drug Deliv Rev  2023,199,114968","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.brainresbull.2016.04.007","volume":"126","author":"Ohno M.","year":"2016","unstructured":"Ohno M.; Alzheimer\u2019s therapy targeting the \u03b2-secretase enzyme BACE1: Benefits and potential limitations from the perspective of animal model studies. Brain Res Bull  2016,126(Pt 2),183-198","journal-title":"Brain Res Bull"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jconrel.2018.04.034","volume":"279","author":"Wang P.","year":"2018","unstructured":"Wang P.; Zheng X.; Guo Q.; Yang P.; Pang X.; Qian K.; Lu W.; Zhang Q.; Jiang X.; Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer\u2019s disease. J Control Release  2018,279,220-233","journal-title":"J Control Release"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"Congdon E.E.","year":"2018","unstructured":"Congdon E.E.; Sigurdsson E.M.; Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol  2018,14(7),399-415","journal-title":"Nat Rev Neurol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2174\/156720510793611592","volume":"7","author":"Iqbal K.","year":"2010","unstructured":"Iqbal K.; Liu F.; Gong C.X.; Grundke-Iqbal I.; Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res  2010,7(8),656-664","journal-title":"Curr Alzheimer Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1007\/s12035-015-9415-8","volume":"53","author":"Zhang C.C.","year":"2016","unstructured":"Zhang C.C.; Xing A.; Tan M.S.; Tan L.; Yu J.T.; The role of MAPT in neurodegenerative diseases: genetics, mechanisms and therapy. Mol Neurobiol  2016,53(7),4893-4904","journal-title":"Mol Neurobiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"15548627.2018.1509607","DOI":"10.1080\/15548627.2018.1509607","volume":"14","author":"Balaji V.","year":"2018","unstructured":"Balaji V.; Kaniyappan S.; Mandelkow E.; Wang Y.; Mandelkow E.M.; Pathological missorting of endogenous MAPT\/Tau in neurons caused by failure of protein degradation systems. Autophagy  2018,14(12),15548627.2018.1509607","journal-title":"Autophagy"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fphar.2012.00014","volume":"3","author":"Solito E.","year":"2012","unstructured":"Solito E.; Sastre M.; Microglia function in Alzheimer\u2019s disease. Front Pharmacol  2012,3,14","journal-title":"Front Pharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"795036","DOI":"10.3389\/fimmu.2021.795036","volume":"12","author":"Li X.","year":"2021","unstructured":"Li X.; Zhang F.; Targeting TREM2 for Parkinson\u2019s disease: where to go? Front Immunol  2021,12,795036","journal-title":"Front Immunol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1093\/hmg\/ddaa179","volume":"29","author":"Griciuc A.","year":"2020","unstructured":"Griciuc A.; Federico A.N.; Natasan J.; Forte A.M.; McGinty D.; Nguyen H.; Volak A.; LeRoy S.; Gandhi S.; Lerner E.P.; Hudry E.; Tanzi R.E.; Maguire C.A.; Gene therapy for Alzheimer\u2019s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation. Hum Mol Genet  2020,29(17),2920-2935","journal-title":"Hum Mol Genet"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1093\/hmg\/ddaa209","volume":"29","author":"Liu W.","year":"2020","unstructured":"Liu W.; Taso O.; Wang R.; Bayram S.; Graham A.C.; Garcia-Reitboeck P.; Mallach A.; Andrews W.D.; Piers T.M.; Botia J.A.; Pocock J.M.; Cummings D.M.; Hardy J.; Edwards F.A.; Salih D.A.; Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions. Hum Mol Genet  2020,29(19),3224-3248","journal-title":"Hum Mol Genet"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12916-019-1299-4","volume":"17","author":"Safieh M.","year":"2019","unstructured":"Safieh M.; Korczyn A.D.; Michaelson D.M.; ApoE4: an emerging therapeutic target for Alzheimer\u2019s disease. BMC Med  2019,17(1),64","journal-title":"BMC Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Yamazaki Y.","year":"2019","unstructured":"Yamazaki Y.; Zhao N.; Caulfield T.R.; Liu C.C.; Bu G.; Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol  2019,15(9),501-518","journal-title":"Nat Rev Neurol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"101111","DOI":"10.1016\/j.mam.2022.101111","volume":"90","author":"Eskandari-Sedighi G.","year":"2023","unstructured":"Eskandari-Sedighi G.; Jung J.; Macauley M.S.; CD33 isoforms in microglia and Alzheimer\u2019s disease: Friend and foe. Mol Aspects Med  2023,90,101111","journal-title":"Mol Aspects Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrd2742","volume":"8","author":"Whitehead K.A.","year":"2009","unstructured":"Whitehead K.A.; Langer R.; Anderson D.G.; Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov  2009,8(2),129-138","journal-title":"Nat Rev Drug Discov"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.2147\/IJN.S215941","volume":"14","author":"dos Santos Rodrigues B.","year":"2019","unstructured":"dos Santos Rodrigues B.; Lakkadwala S.; Kanekiyo T.; Singh J.; Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties. Int J Nanomedicine  2019,14,6497-6517","journal-title":"Int J Nanomedicine"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev-chembioeng-061010-114133","volume":"2","author":"Whitehead K.A.","year":"2011","unstructured":"Whitehead K.A.; Dahlman J.E.; Langer R.S.; Anderson D.G.; Silencing or stimulation? siRNA delivery and the immune system. Annu Rev Chem Biomol Eng  2011,2(1),77-96","journal-title":"Annu Rev Chem Biomol Eng"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1365-2362.2010.02400.x","volume":"41","author":"Chen S.H.","year":"2011","unstructured":"Chen S.H.; Zhaori G.; Potential clinical applications of siRNA technique: benefits and limitations. Eur J Clin Invest  2011,41(2),221-232","journal-title":"Eur J Clin Invest"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/138920011794520017","volume":"12","author":"Scaggiante B.","year":"2011","unstructured":"Scaggiante B.; Dapas B.; Farra R.; Grassi M.; Pozzato G.; Giansante C.; Grassi G.; Grassi G.; Improving siRNA bio-distribution and minimizing side effects. Curr Drug Metab  2011,12(1),11-23","journal-title":"Curr Drug Metab"},{"key":"ref=54","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-3112-5","author":"Shum K.","year":"2016","unstructured":"Shum K.; Rossi J.; SiRNA delivery methods. Methods in Molecular Biology  2016","journal-title":"Methods in Molecular Biology"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1517\/17425247.2011.559223","volume":"8","author":"Yuan X.","year":"2011","unstructured":"Yuan X.; Naguib S.; Wu Z.; Recent advances of siRNA delivery by nanoparticles. Expert Opin Drug Deliv  2011,8(4),521-536","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=56","author":"Aundhia C.","year":"2024","unstructured":"Aundhia C.; Shah N.; Talele C.; Zanwar A.; Kumari M.; Patil S.; Enhancing Gene Therapy through Ultradeformable Vesicles for Efficient siRNA Delivery. Pharm Nanotechnol  2024","journal-title":"Pharm Nanotechnol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"48","DOI":"10.7150\/oncm.25785","volume":"3","author":"Marquez A.R.","year":"2018","unstructured":"Marquez A.R.; Madu C.O.; Lu Y.; An overview of various carriers for siRNA delivery. Oncomedicine  2018,3,48-58","journal-title":"Oncomedicine"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"237","DOI":"10.21873\/anticanres.13103","volume":"39","author":"Yuan B.","year":"2019","unstructured":"Yuan B.; Zhao Y.; Dong S.; Sun Y.; Hao F.; Xie J.; Teng L.; Lee R.J.; Fu Y.; Bi Y.; Cell-penetrating peptide-coated liposomes for drug delivery across the blood\u2013brain barrier. Anticancer Res  2019,39(1),237-243","journal-title":"Anticancer Res"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/1389201015666140617092552","volume":"15","author":"Gao H.","year":"2014","unstructured":"Gao H.; Zhang Q.; Yu Z.; He Q.; Cell-penetrating peptide-based intelligent liposomal systems for enhanced drug delivery. Curr Pharm Biotechnol  2014,15(3),210-219","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","volume":"23","author":"Zu H.","year":"2021","unstructured":"Zu H.; Gao D.; Non-viral vectors in gene therapy: recent development, challenges, and prospects. AAPS J  2021,23(4),78","journal-title":"AAPS J"},{"key":"ref=61","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-095-9_1","author":"Warnock J.N.","year":"2011","unstructured":"Warnock J.N.; Daigre C.; Al-Rubeai M.; Introduction to viral vectors. Viral vectors for gene therapy: methods and protocols  2011","journal-title":"Viral vectors for gene therapy: methods and protocols"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.addr.2009.04.004","volume":"61","author":"Rao D.D.","year":"2009","unstructured":"Rao D.D.; Vorhies J.S.; Senzer N.; Nemunaitis J.; siRNA vs. shRNA: Similarities and differences. Adv Drug Deliv Rev  2009,61(9),746-759","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=63","doi-asserted-by":"publisher","DOI":"10.1002\/9783527636778","author":"Cabianca D.S.","year":"2012","unstructured":"Cabianca D.S.; Gabellini D.; Alternative pre-mRNA Splicing: Theory and Protocols Alternative pre-mRNA Splicing  2012","journal-title":"Alternative pre-mRNA Splicing"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1007\/s11095-011-0608-1","volume":"28","author":"Singh S.","year":"2011","unstructured":"Singh S.; Narang A.S.; Mahato R.I.; Subcellular Fate and Off-Target Effects of siRNA, shRNA, and miRNA. Pharm Res  2011,28(12),2996-3015","journal-title":"Pharm Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nsmb.2827","volume":"21","author":"White E.","year":"2014","unstructured":"White E.; Schlackow M.; Kamieniarz-Gdula K.; Proudfoot N.J.; Gullerova M.; Human nuclear Dicer restricts the deleterious accumulation of endogenous double-stranded RNA. Nat Struct Mol Biol  2014,21(6),552-559","journal-title":"Nat Struct Mol Biol"},{"key":"ref=66","first-page":"1","volume":"36","author":"Vannucci L.","year":"2013","unstructured":"Vannucci L.; Lai M.; Chiuppesi F.; Ceccherini-Nelli L.; Pistello M.; Viral vectors: a look back and ahead on gene transfer technology. New Microbiol  2013,36(1),1-22","journal-title":"New Microbiol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1039\/D0BM01278E","volume":"9","author":"Conniot J.","year":"2021","unstructured":"Conniot J.; Talebian S.; Sim\u00f5es S.; Ferreira L.; Conde J.; Revisiting gene delivery to the brain: silencing and editing. Biomater Sci  2021,9(4),1065-1087","journal-title":"Biomater Sci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"122065","DOI":"10.1016\/j.biomaterials.2023.122065","volume":"296","author":"Krishnan N.","year":"2023","unstructured":"Krishnan N.; Peng F.X.; Mohapatra A.; Fang R.H.; Zhang L.; Genetically engineered cellular nanoparticles for biomedical applications. Biomaterials  2023,296,122065","journal-title":"Biomaterials"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1111\/ejn.16336","volume":"59","author":"Ahmed T.","year":"2024","unstructured":"Ahmed T.; Lipid nanoparticle mediated small interfering RNA delivery as a potential therapy for Alzheimer\u2019s disease. Eur J Neurosci  2024,59(11),2915-2954","journal-title":"Eur J Neurosci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11095-007-9431-0","volume":"25","author":"Kwon I.","year":"2008","unstructured":"Kwon I.; Schaffer D.V.; Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res  2008,25(3),489-499","journal-title":"Pharm Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2174\/1566523023347797","volume":"2","author":"Nicklin S.","year":"2002","unstructured":"Nicklin S.; Baker A.; Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy. Curr Gene Ther  2002,2(3),273-293","journal-title":"Curr Gene Ther"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2174\/1566523222666220328142427","volume":"23","author":"Mani S.","year":"2023","unstructured":"Mani S.; Jindal D.; Singh M.; Gene therapy, a potential therapeutic tool for neurological and neuropsychiatric disorders: applications, challenges and future perspective. Curr Gene Ther  2023,23(1),20-40","journal-title":"Curr Gene Ther"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrg3763","volume":"15","author":"Yin H.","year":"2014","unstructured":"Yin H.; Kanasty R.L.; Eltoukhy A.A.; Vegas A.J.; Dorkin J.R.; Anderson D.G.; Non-viral vectors for gene-based therapy. Nat Rev Genet  2014,15(8),541-555","journal-title":"Nat Rev Genet"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.coviro.2014.07.008","volume":"8","author":"Zinn E.","year":"2014","unstructured":"Zinn E.; Vandenberghe L.H.; Adeno-associated virus: fit to serve. Curr Opin Virol  2014,8,90-97","journal-title":"Curr Opin Virol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2174\/156652311796150354","volume":"11","author":"Mingozzi F.","year":"2011","unstructured":"Mingozzi F.; High K.A.; Immune responses to AAV in clinical trials. Curr Gene Ther  2011,11(4),321-330","journal-title":"Curr Gene Ther"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","volume":"30","author":"Muhuri M.","year":"2022","unstructured":"Muhuri M.; Levy D.I.; Schulz M.; McCarty D.; Gao G.; Durability of transgene expression after rAAV gene therapy. Mol Ther  2022,30(4),1364-1380","journal-title":"Mol Ther"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.coviro.2016.07.004","volume":"21","author":"Gil-Farina I.","year":"2016","unstructured":"Gil-Farina I.; Schmidt M.; Interaction of vectors and parental viruses with the host genome. Curr Opin Virol  2016,21,35-40","journal-title":"Curr Opin Virol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/mt.2009.122","volume":"17","author":"Wanisch K.","year":"2009","unstructured":"Wanisch K.; Y\u00e1\u00f1ez-Mu\u00f1oz R.J.; Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther  2009,17(8),1316-1332","journal-title":"Mol Ther"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/biomedicines10010107","volume":"10","author":"Gurumoorthy N.","year":"2022","unstructured":"Gurumoorthy N.; Nordin F.; Tye G.J.; Wan Kamarul Zaman W.S.; Ng M.H.; Non-integrating lentiviral vectors in clinical applications: A glance through. Biomedicines  2022,10(1),107","journal-title":"Biomedicines"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3390\/v12040460","volume":"12","author":"Mijanovi\u0107 O.","year":"2020","unstructured":"Mijanovi\u0107 O.; Brankovi\u0107 A.; Borovjagin A.V.; Butnaru D.V.; Bezrukov E.A.; Sukhanov R.B.; Shpichka A.; Timashev P.; Ulasov I.; Battling neurodegenerative diseases with adeno-associated virus-based approaches. Viruses  2020,12(4),460","journal-title":"Viruses"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/brainsci10020119","volume":"10","author":"Perez B.A.","year":"2020","unstructured":"Perez B.A.; Shutterly A.; Chan Y.K.; Byrne B.J.; Corti M.; Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases. Brain Sci  2020,10(2),119","journal-title":"Brain Sci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"14051","DOI":"10.1038\/mtm.2014.51","volume":"1","author":"Hinderer C.","year":"2014","unstructured":"Hinderer C.; Bell P.; Vite C.H.; Louboutin J.P.; Grant R.; Bote E.; Yu H.; Pukenas B.; Hurst R.; Wilson J.M.; Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Mol Ther Methods Clin Dev  2014,1,14051","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s13311-014-0299-5","volume":"11","author":"Maguire C.A.","year":"2014","unstructured":"Maguire C.A.; Ramirez S.H.; Merkel S.F.; Sena-Esteves M.; Breakefield X.O.; Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics  2014,11(4),817-839","journal-title":"Neurotherapeutics"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mt.2009.255","volume":"18","author":"Wu Z.","year":"2010","unstructured":"Wu Z.; Yang H.; Colosi P.; Effect of genome size on AAV vector packaging. Mol Ther  2010,18(1),80-86","journal-title":"Mol Ther"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/brv.12718","volume":"96","author":"Whitehead M.","year":"2021","unstructured":"Whitehead M.; Osborne A.; Yu-Wai-Man P.; Martin K.; Humoral immune responses to AAV gene therapy in the ocular compartment. Biol Rev Camb Philos Soc  2021,96(4),1616-1644","journal-title":"Biol Rev Camb Philos Soc"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.visres.2006.11.026","volume":"47","author":"Gorbatyuk M.","year":"2007","unstructured":"Gorbatyuk M.; Justilien V.; Liu J.; Hauswirth W.W.; Lewin A.S.; Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vision Res  2007,47(9),1202-1208","journal-title":"Vision Res"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.apsb.2018.12.010","volume":"9","author":"Guo Q.","year":"2019","unstructured":"Guo Q.; Zheng X.; Yang P.; Pang X.; Qian K.; Wang P.; Xu S.; Sheng D.; Wang L.; Cao J.; Lu W.; Zhang Q.; Jiang X.; Small interfering RNA delivery to the neurons near the amyloid plaques for improved treatment of Alzheimer\u05f3s disease. Acta Pharm Sin B  2019,9(3),590-603","journal-title":"Acta Pharm Sin B"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.biomaterials.2015.11.066","volume":"80","author":"Zhang C.","year":"2016","unstructured":"Zhang C.; Yao T.; Zheng Y.; Li Z.; Zhang Q.; Zhang L.; Zhou D.; Development of next generation adeno-associated viral vectors capable of selective tropism and efficient gene delivery. Biomaterials  2016,80,134-145","journal-title":"Biomaterials"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/v12101106","volume":"12","author":"Munis A.M.","year":"2020","unstructured":"Munis A.M.; Gene therapy applications of non-human lentiviral vectors. Viruses  2020,12(10),1106","journal-title":"Viruses"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12967-016-1047-x","volume":"14","author":"Vargas J.E.","year":"2016","unstructured":"Vargas J.E.; Chicaybam L.; Stein R.T.; Tanuri A.; Delgado-Ca\u00f1edo A.; Bonamino M.H.; Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives. J Transl Med  2016,14(1),288","journal-title":"J Transl Med"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00005-010-0063-4","volume":"58","author":"Escors D.","year":"2010","unstructured":"Escors D.; Breckpot K.; Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz)  2010,58(2),107-119","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1023\/A:1021022629126","volume":"26","author":"Vodicka M.A.","year":"2001","unstructured":"Vodicka M.A.; Determinants for lentiviral infection of non-dividing cells. Somat Cell Mol Genet  2001,26(1\/6),35-49","journal-title":"Somat Cell Mol Genet"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"16505","DOI":"10.1073\/pnas.0908397106","volume":"106","author":"Kanninen K.","year":"2009","unstructured":"Kanninen K.; Heikkinen R.; Malm T.; Rolova T.; Kuhmonen S.; Leinonen H.; Yl\u00e4-Herttuala S.; Tanila H.; Levonen A.L.; Koistinaho M.; Koistinaho J.; Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci USA  2009,106(38),16505-16510","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.3892\/etm.2018.6359","volume":"16","author":"Zhang W.","year":"2018","unstructured":"Zhang W.; Zhao H.; Wu Q.; Xu W.; Xia M.; Knockdown of BACE1 AS by siRNA improves memory and learning behaviors in Alzheimer\u2019s disease animal model. Exp Ther Med  2018,16(3),2080-2086","journal-title":"Exp Ther Med"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nn1531","volume":"8","author":"Singer O.","year":"2005","unstructured":"Singer O.; Marr R.A.; Rockenstein E.; Crews L.; Coufal N.G.; Gage F.H.; Verma I.M.; Masliah E.; Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci  2005,8(10),1343-1349","journal-title":"Nat Neurosci"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"9021","DOI":"10.1038\/srep09021","volume":"5","author":"Sanber K.S.","year":"2015","unstructured":"Sanber K.S.; Knight S.B.; Stephen S.L.; Bailey R.; Escors D.; Minshull J.; Santilli G.; Thrasher A.J.; Collins M.K.; Takeuchi Y.; Construction of stable packaging cell lines for clinical lentiviral vector production. Sci Rep  2015,5(1),9021","journal-title":"Sci Rep"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1089\/hum.2012.229","volume":"24","author":"Schambach A.","year":"2013","unstructured":"Schambach A.; Zychlinski D.; Ehrnstroem B.; Baum C.; Biosafety features of lentiviral vectors. Hum Gene Ther  2013,24(2),132-142","journal-title":"Hum Gene Ther"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/1541-7786.MCR-13-0244","volume":"11","author":"Ranzani M.","year":"2013","unstructured":"Ranzani M.; Annunziato S.; Adams D.J.; Montini E.; Cancer gene discovery: exploiting insertional mutagenesis. Mol Cancer Res  2013,11(10),1141-1158","journal-title":"Mol Cancer Res"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/sj.gt.3302570","volume":"12","author":"Sinn P.L.","year":"2005","unstructured":"Sinn P.L.; Sauter S.L.; McCray P.B.; Gene Therapy Progress and Prospects: Development of improved lentiviral and retroviral vectors \u2013 design, biosafety, and production. Gene Ther  2005,12(14),1089-1098","journal-title":"Gene Ther"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3390\/v12101103","volume":"12","author":"Apolonia L.","year":"2020","unstructured":"Apolonia L.; The old and the new: prospects for non-integrating lentiviral vector technology. Viruses  2020,12(10),1103","journal-title":"Viruses"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1089\/104454902762053855","volume":"21","author":"Lai C.M.","year":"2002","unstructured":"Lai C.M.; Lai Y.K.Y.; Rakoczy P.E.; Adenovirus and adeno-associated virus vectors. DNA Cell Biol  2002,21(12),895-913","journal-title":"DNA Cell Biol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/72594","volume":"18","author":"Link C.J.","year":"2000","unstructured":"Link C.J.; Adenoviral vectors go retro. Nat Biotechnol  2000,18(2),150-151","journal-title":"Nat Biotechnol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1006\/mthe.2000.0062","volume":"1","author":"Krasnykh V.N.","year":"2000","unstructured":"Krasnykh V.N.; Douglas J.T.; van Beusechem V.W.; Genetic targeting of adenoviral vectors. Mol Ther  2000,1(5),391-405","journal-title":"Mol Ther"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/156652311796150372","volume":"11","author":"Ahi Y.S.","year":"2011","unstructured":"Ahi Y.S.; Bangari D.S.; Mittal S.K.; Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther  2011,11(4),307-320","journal-title":"Curr Gene Ther"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/gt.2009.148","volume":"17","author":"Nayak S.","year":"2010","unstructured":"Nayak S.; Herzog R.W.; Progress and prospects: immune responses to viral vectors. Gene Ther  2010,17(3),295-304","journal-title":"Gene Ther"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2174\/156652321305131212125338","volume":"13","author":"Cots D.","year":"2013","unstructured":"Cots D.; Bosch A.; Chill\u00f3n M.; Helper dependent adenovirus vectors: progress and future prospects. Curr Gene Ther  2013,13(5),370-381","journal-title":"Curr Gene Ther"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/156652306776359478","volume":"6","author":"Bangari D.","year":"2006","unstructured":"Bangari D.; Mittal S.; Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther  2006,6(2),215-226","journal-title":"Curr Gene Ther"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"397243","DOI":"10.5402\/2013\/397243","volume":"2013","author":"Lim F.","year":"2013","unstructured":"Lim F.; HSV-1 as a model for emerging gene delivery vehicles. Int Scholarly Res Not  2013,2013,397243","journal-title":"Int Scholarly Res Not"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1146\/annurev-virology-100114-055212","volume":"2","author":"Rao V.B.","year":"2015","unstructured":"Rao V.B.; Feiss M.; Mechanisms of DNA packaging by large double-stranded DNA viruses. Annu Rev Virol  2015,2(1),351-378","journal-title":"Annu Rev Virol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/0042-6822(88)90160-2","volume":"166","author":"Paterson T.","year":"1988","unstructured":"Paterson T.; Everett R.D.; Mutational dissection of the HSV-1 immediate-early protein Vmw175 involved in transcriptional transactivation and repression. Virology  1988,166(1),186-196","journal-title":"Virology"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1089\/104454902762053864","volume":"21","author":"Burton E.A.","year":"2002","unstructured":"Burton E.A.; Fink D.J.; Glorioso J.C.; Gene delivery using herpes simplex virus vectors. DNA Cell Biol  2002,21(12),915-936","journal-title":"DNA Cell Biol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/mt.2010.27","volume":"18","author":"Kim S.S.","year":"2010","unstructured":"Kim S.S.; Ye C.; Kumar P.; Chiu I.; Subramanya S.; Wu H.; Shankar P.; Manjunath N.; Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther  2010,18(5),993-1001","journal-title":"Mol Ther"},{"key":"ref=113","first-page":"123","volume":"4","author":"Manservigi R.","year":"2010","unstructured":"Manservigi R.; Argnani R.; Marconi P.; HSV recombinant vectors for gene therapy. Open Virol J  2010,4,123-156","journal-title":"Open Virol J"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2174\/156652311797415845","volume":"11","author":"de Silva S.","year":"2011","unstructured":"de Silva S.; Bowers W.J.; Targeting the central nervous system with herpes simplex virus\/Sleeping Beauty hybrid amplicon vectors. Curr Gene Ther  2011,11(5),332-340","journal-title":"Curr Gene Ther"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1525-0016(02)00036-9","volume":"7","author":"Olschowka J.A.","year":"2003","unstructured":"Olschowka J.A.; Bowers W.J.; Hurley S.D.; Mastrangelo M.A.; Federoff H.J.; Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. Mol Ther  2003,7(2),218-227","journal-title":"Mol Ther"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2174\/1566523044578077","volume":"4","author":"Papadakis E.","year":"2004","unstructured":"Papadakis E.; Nicklin S.; Baker A.; White S.; Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther  2004,4(1),89-113","journal-title":"Curr Gene Ther"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1479-0556-2-9","volume":"2","author":"Anson D.S.","year":"2004","unstructured":"Anson D.S.; The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther  2004,2(1),9","journal-title":"Genet Vaccines Ther"},{"key":"ref=118","first-page":"4239","volume":"10","author":"Miller D.G.","year":"1990","unstructured":"Miller D.G.; Adam M.A.; Miller A.D.; Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol  1990,10(8),4239-4242","journal-title":"Mol Cell Biol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrn1104","volume":"4","author":"Davidson B.L.","year":"2003","unstructured":"Davidson B.L.; Breakefield X.O.; Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci  2003,4(5),353-364","journal-title":"Nat Rev Neurosci"},{"key":"ref=120","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-53457-2_2","author":"Cesana D.","year":"2017","unstructured":"Cesana D.; Volpin M.; Secanechia Y.N.; Montini E.;  Safety and efficacy of retroviral and lentiviral vectors for gene therapy  2017","journal-title":"Safety and efficacy of retroviral and lentiviral vectors for gene therapy"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plasmid.2018.05.002","volume":"98","author":"Mansouri M.","year":"2018","unstructured":"Mansouri M.; Berger P.; Baculovirus for gene delivery to mammalian cells: Past, present and future. Plasmid  2018,98,1-7","journal-title":"Plasmid"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"2000021","DOI":"10.1002\/biot.202000021","volume":"16","author":"Joshi P.R.H.","year":"2021","unstructured":"Joshi P.R.H.; Venereo-Sanchez A.; Chahal P.S.; Kamen A.A.; Advancements in molecular design and bioprocessing of recombinant adeno\u2010associated virus gene delivery vectors using the insect\u2010cell baculovirus expression platform. Biotechnol J  2021,16(4),2000021","journal-title":"Biotechnol J"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.biotechadv.2011.04.004","volume":"29","author":"Chen C.Y.","year":"2011","unstructured":"Chen C.Y.; Lin C.Y.; Chen G.Y.; Hu Y.C.; Baculovirus as a gene delivery vector: Recent understandings of molecular alterations in transduced cells and latest applications. Biotechnol Adv  2011,29(6),618-631","journal-title":"Biotechnol Adv"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/156652308783688509","volume":"8","author":"Hu Y.C.","year":"2008","unstructured":"Hu Y.C.; Baculoviral vectors for gene delivery: a review. Curr Gene Ther  2008,8(1),54-65","journal-title":"Curr Gene Ther"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0065-3527(06)68008-1","volume":"68","author":"Hu Y.C.","year":"2006","unstructured":"Hu Y.C.; Baculovirus vectors for gene therapy. Adv Virus Res  2006,68,287-320","journal-title":"Adv Virus Res"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"215","DOI":"10.21775\/cimb.034.215","volume":"34","author":"Possee R.D.","year":"2020","unstructured":"Possee R.D.; Chambers A.C.; Graves L.P.; Aksular M.; King L.A.; Recent developments in the use of baculovirus expression vectors. Curr Issues Mol Biol  2020,34(1),215-230","journal-title":"Curr Issues Mol Biol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1128\/JVI.72.6.5025-5034.1998","volume":"72","author":"Palombo F.","year":"1998","unstructured":"Palombo F.; Monciotti A.; Recchia A.; Cortese R.; Ciliberto G.; La Monica N.; Site-specific integration in mammalian cells mediated by a new hybrid baculovirus-adeno-associated virus vector. J Virol  1998,72(6),5025-5034","journal-title":"J Virol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.rvsc.2006.03.009","volume":"82","author":"Fa\u00edsca P.","year":"2007","unstructured":"Fa\u00edsca P.; Desmecht D.; Sendai virus, the mouse parainfluenza type 1: A longstanding pathogen that remains up-to-date. Res Vet Sci  2007,82(1),115-125","journal-title":"Res Vet Sci"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.gene.2018.11.069","volume":"686","author":"Haridhasapavalan K.K.","year":"2019","unstructured":"Haridhasapavalan K.K.; Borgohain M.P.; Dey C.; Saha B.; Narayan G.; Kumar S.; Thummer R.P.; An insight into non-integrative gene delivery approaches to generate transgene-free induced pluripotent stem cells. Gene  2019,686,146-159","journal-title":"Gene"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1038\/sj.gt.3303032","volume":"14","author":"Ban H.","year":"2007","unstructured":"Ban H.; Inoue M.; Griesenbach U.; Munkonge F.; Chan M.; Iida A.; Alton E.W F W.; Hasegawa M.; Expression and maturation of Sendai virus vector-derived CFTR protein: functional and biochemical evidence using a GFP-CFTR fusion protein. Gene Ther  2007,14(24),1688-1694","journal-title":"Gene Ther"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/vaccines2030624","volume":"2","author":"Ura T.","year":"2014","unstructured":"Ura T.; Okuda K.; Shimada M.; Developments in viral vector-based vaccines. Vaccines (Basel)  2014,2(3),624-641","journal-title":"Vaccines (Basel)"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/bit.20562","volume":"92","author":"Lee G.K.","year":"2005","unstructured":"Lee G.K.; Maheshri N.; Kaspar B.; Schaffer D.V.; PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol Bioeng  2005,92(1),24-34","journal-title":"Biotechnol Bioeng"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jconrel.2005.07.019","volume":"108","author":"Le H.T.","year":"2005","unstructured":"Le H.T.; Yu Q.C.; Wilson J.M.; Croyle M.A.; Utility of PEGylated recombinant adeno-associated viruses for gene transfer. J Control Release  2005,108(1),161-177","journal-title":"J Control Release"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"8150","DOI":"10.1128\/JVI.72.10.8150-8157.1998","volume":"72","author":"Miyoshi H.","year":"1998","unstructured":"Miyoshi H.; Bl\u00f6mer U.; Takahashi M.; Gage F.H.; Verma I.M.; Development of a self-inactivating lentivirus vector. J Virol  1998,72(10),8150-8157","journal-title":"J Virol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3390\/biom10060839","volume":"10","author":"Yip B.","year":"2020","unstructured":"Yip B.; Recent advances in CRISPR\/Cas9 delivery strategies. Biomolecules  2020,10(6),839","journal-title":"Biomolecules"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"565","DOI":"10.5483\/BMBRep.2020.53.11.185","volume":"53","author":"Liu J.","year":"2020","unstructured":"Liu J.; Seol D.W.; Helper virus-free gutless adenovirus (HF-GLAd): a new platform for gene therapy. BMB Rep  2020,53(11),565-575","journal-title":"BMB Rep"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2174\/156652306777591992","volume":"6","author":"Frenkel N.","year":"2006","unstructured":"Frenkel N.; The history of the HSV amplicon: from naturally occurring defective genomes to engineered amplicon vectors. Curr Gene Ther  2006,6(3),277-299","journal-title":"Curr Gene Ther"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0301-0082(98)00007-0","volume":"55","author":"Hermens W.T.J.M.C.","year":"1998","unstructured":"Hermens W.T.J.M.C.; Verhaagen J.; Viral vectors, tools for gene transfer in the nervous system. Prog Neurobiol  1998,55(4),399-432","journal-title":"Prog Neurobiol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/macp.201500464","volume":"217","author":"Whitlow J.","year":"2016","unstructured":"Whitlow J.; Pacelli S.; Paul A.; Polymeric nanohybrids as a new class of therapeutic biotransporters. Macromol Chem Phys  2016,217(11),1245-1259","journal-title":"Macromol Chem Phys"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/jgm.938","volume":"8","author":"Yoshizaki M.","year":"2006","unstructured":"Yoshizaki M.; Hironaka T.; Iwasaki H.; Ban H.; Tokusumi Y.; Iida A.; Naked Sendai virus vector lacking all of the envelope-related genes: reduced cytopathogenicity and immunogenicity. J Gene Med  2006,8(9),1151-1159","journal-title":"J Gene Med"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"e10713","DOI":"10.1002\/btm2.10713","author":"Chen Q.","year":"2024","unstructured":"Chen Q.; Huo K.G.; Ji S.M.; Pang S.D.; Sun T.Y.; Niu Y.; Jiang Z-H.; Zhang P.; Han S-X.; Li J-Y.; Unleashing the potential of MRNA: Overcoming delivery challenges with nanoparticles. Bioeng Transl Med  2024,e10713","journal-title":"Bioeng Transl Med"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/gt.2008.183","volume":"16","author":"Gill D.R.","year":"2009","unstructured":"Gill D.R.; Pringle I.A.; Hyde S.C.; Progress and Prospects: The design and production of plasmid vectors. Gene Ther  2009,16(2),165-171","journal-title":"Gene Ther"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/sj.gt.3301905","volume":"10","author":"K\u00fcgler S.","year":"2003","unstructured":"K\u00fcgler S.; Kilic E.; B\u00e4hr M.; Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Ther  2003,10(4),337-347","journal-title":"Gene Ther"},{"key":"ref=144","first-page":"732","volume":"1809","author":"Liu Y.P.","year":"2011","unstructured":"Liu Y.P.; Berkhout B.; miRNA cassettes in viral vectors: problems and solutions. Biochimica et Biophysica Acta (BBA)-. Gene Regulatory Mechanisms  2011,1809(11-12),732-745","journal-title":"Gene Regulatory Mechanisms"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.7150\/thno.42640","volume":"10","author":"Leng Q.","year":"2020","unstructured":"Leng Q.; Chen L.; Lv Y.; RNA-based scaffolds for bone regeneration: application and mechanisms of mRNA, miRNA and siRNA. Theranostics  2020,10(7),3190-3205","journal-title":"Theranostics"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"100899","DOI":"10.1016\/j.mgene.2021.100899","volume":"29","author":"Watts A.","year":"2021","unstructured":"Watts A.; Sankaranarayanan S.; Watts A.; Raipuria R.K.; Optimizing protein expression in heterologous system: Strategies and tools. Meta Gene  2021,29,100899","journal-title":"Meta Gene"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.tibtech.2004.04.006","volume":"22","author":"Gustafsson C.","year":"2004","unstructured":"Gustafsson C.; Govindarajan S.; Minshull J.; Codon bias and heterologous protein expression. Trends Biotechnol  2004,22(7),346-353","journal-title":"Trends Biotechnol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.coviro.2016.08.001","volume":"21","author":"Berry G.E.","year":"2016","unstructured":"Berry G.E.; Asokan A.; Cellular transduction mechanisms of adeno-associated viral vectors. Curr Opin Virol  2016,21,54-60","journal-title":"Curr Opin Virol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11011-020-00630-2","volume":"36","author":"Liu D.","year":"2021","unstructured":"Liu D.; Zhu M.; Zhang Y.; Diao Y.; Crossing the blood-brain barrier with AAV vectors. Metab Brain Dis  2021,36(1),45-52","journal-title":"Metab Brain Dis"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1248\/cpb.c19-00854","volume":"68","author":"Tashima T.","year":"2020","unstructured":"Tashima T.; Smart strategies for therapeutic agent delivery into brain across the blood\u2013brain barrier using receptor-mediated transcytosis. Chem Pharm Bull (Tokyo)  2020,68(4),316-325","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1360302","DOI":"10.3389\/fddev.2024.1360302","volume":"4","author":"Haqqani A.S.","year":"2024","unstructured":"Haqqani A.S.; B\u00e9langer K.; Stanimirovic D.B.; Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria. Frontiers in Drug Delivery  2024,4,1360302","journal-title":"Frontiers in Drug Delivery"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.adm8386","volume":"384","author":"Huang Q.","year":"2024","unstructured":"Huang Q.; Chan K.Y.; Wu J.; Botticello-Romero N.R.; Zheng Q.; Lou S.; Keyes C.; Svanbergsson A.; Johnston J.; Mills A.; Lin C.Y.; Brauer P.P.; Clouse G.; Pacouret S.; Harvey J.W.; Beddow T.; Hurley J.K.; Tobey I.G.; Powell M.; Chen A.T.; Barry A.J.; Eid F.E.; Chan Y.A.; Deverman B.E.; An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery. Science  2024,384(6701),1220-1227","journal-title":"Science"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.bbagen.2011.10.013","volume":"1820","author":"Gkouvatsos K.","year":"2012","unstructured":"Gkouvatsos K.; Papanikolaou G.; Pantopoulos K.; Regulation of iron transport and the role of transferrin. Biochim Biophys Acta, Gen Subj  2012,1820(3),188-202","journal-title":"Biochim Biophys Acta, Gen Subj"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pharmthera.2012.07.006","volume":"136","author":"Banks W.A.","year":"2012","unstructured":"Banks W.A.; Owen J.B.; Erickson M.A.; Insulin in the brain: There and back again. Pharmacol Ther  2012,136(1),82-93","journal-title":"Pharmacol Ther"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1128\/JVI.02309-08","volume":"83","author":"Johnson J.S.","year":"2009","unstructured":"Johnson J.S.; Samulski R.J.; Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol  2009,83(6),2632-2644","journal-title":"J Virol"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"Suk J.S.","year":"2016","unstructured":"Suk J.S.; Xu Q.; Kim N.; Hanes J.; Ensign L.M.; PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev  2016,99(Pt A),28-51","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jconrel.2022.01.008","volume":"342","author":"Yan Y.","year":"2022","unstructured":"Yan Y.; Liu X.Y.; Lu A.; Wang X.Y.; Jiang L.X.; Wang J.C.; Non-viral vectors for RNA delivery. J Control Release  2022,342,241-279","journal-title":"J Control Release"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1039\/D1NR06939J","volume":"14","author":"Tasset A.","year":"2022","unstructured":"Tasset A.; Bellamkonda A.; Wang W.; Pyatnitskiy I.; Ward D.; Peppas N.; Wang H.; Overcoming barriers in non-viral gene delivery for neurological applications. Nanoscale  2022,14(10),3698-3719","journal-title":"Nanoscale"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/smll.201201390","volume":"9","author":"Duan X.","year":"2013","unstructured":"Duan X.; Li Y.; Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small  2013,9(9-10),1521-1532","journal-title":"Small"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"110770","DOI":"10.1016\/j.colsurfb.2019.110770","volume":"187","author":"Gajbhiye K.R.","year":"2020","unstructured":"Gajbhiye K.R.; Pawar A.; Mahadik K.R.; Gajbhiye V.; PEGylated nanocarriers: A promising tool for targeted delivery to the brain. Colloids Surf B Biointerfaces  2020,187,110770","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"2001238","DOI":"10.1002\/adhm.202001238","volume":"10","author":"Wang Y.","year":"2021","unstructured":"Wang Y.; Bruggeman K.F.; Franks S.; Gautam V.; Hodgetts S.I.; Harvey A.R.; Williams R.J.; Nisbet D.R.; Is viral vector gene delivery more effective using biomaterials? Adv Healthc Mater  2021,10(1),2001238","journal-title":"Adv Healthc Mater"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s11095-012-0874-6","volume":"30","author":"Bao Y.","year":"2013","unstructured":"Bao Y.; Jin Y.; Chivukula P.; Zhang J.; Liu Y.; Liu J.; Clamme J.P.; Mahato R.I.; Ng D.; Ying W.; Wang Y.; Yu L.; Effect of PEGylation on biodistribution and gene silencing of siRNA\/lipid nanoparticle complexes. Pharm Res  2013,30(2),342-351","journal-title":"Pharm Res"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/0023210-200923010-00003","volume":"23","author":"Patel M.M.","year":"2009","unstructured":"Patel M.M.; Goyal B.R.; Bhadada S.V.; Bhatt J.S.; Amin A.F.; Getting into the Brain. CNS Drugs  2009,23(1),35-58","journal-title":"CNS Drugs"},{"key":"ref=164","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/164_2020_403","author":"Helms H.C.C.","year":"2020","unstructured":"Helms H.C.C.; Kristensen M.; Saaby L.; Fricker G.; Brodin B.; Drug delivery strategies to overcome the blood\u2013brain barrier (BBB). Physiology, Pharmacology and Pathology of the Blood-Brain Barrier  2020,151-183","journal-title":"Physiology, Pharmacology and Pathology of the Blood-Brain Barrier"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jconrel.2015.08.059","volume":"219","author":"Timbie K.F.","year":"2015","unstructured":"Timbie K.F.; Mead B.P.; Price R.J.; Drug and gene delivery across the blood\u2013brain barrier with focused ultrasound. J Control Release  2015,219,61-75","journal-title":"J Control Release"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fphar.2019.00086","volume":"10","author":"Chen K.T.","year":"2019","unstructured":"Chen K.T.; Wei K.C.; Liu H.L.; Theranostic strategy of focused ultrasound induced blood-brain barrier opening for CNS disease treatment. Front Pharmacol  2019,10,86","journal-title":"Front Pharmacol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/pharmaceutics7030275","volume":"7","author":"Meairs S.","year":"2015","unstructured":"Meairs S.; Facilitation of drug transport across the blood\u2013brain barrier with ultrasound and microbubbles. Pharmaceutics  2015,7(3),275-293","journal-title":"Pharmaceutics"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1016\/j.biomaterials.2013.01.099","volume":"34","author":"Fan C.H.","year":"2013","unstructured":"Fan C.H.; Ting C.Y.; Lin H.J.; Wang C.H.; Liu H.L.; Yen T.C.; Yeh C.K.; SPIO-conjugated, doxorubicin-loaded microbubbles for concurrent MRI and focused-ultrasound enhanced brain-tumor drug delivery. Biomaterials  2013,34(14),3706-3715","journal-title":"Biomaterials"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jconrel.2021.07.042","volume":"337","author":"Ji R.","year":"2021","unstructured":"Ji R.; Karakatsani M.E.; Burgess M.; Smith M.; Murillo M.F.; Konofagou E.E.; Cavitation-modulated inflammatory response following focused ultrasound blood-brain barrier opening. J Control Release  2021,337,458-471","journal-title":"J Control Release"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"2004025","DOI":"10.1002\/advs.202004025","volume":"8","author":"Ruan S.","year":"2021","unstructured":"Ruan S.; Zhou Y.; Jiang X.; Gao H.; Rethinking CRITID procedure of brain targeting drug delivery: circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internalization, and drug release. Adv Sci (Weinh)  2021,8(9),2004025","journal-title":"Adv Sci (Weinh)"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"eabf7390","DOI":"10.1126\/sciadv.abf7390","volume":"7","author":"Guo Y.","year":"2021","unstructured":"Guo Y.; Lee H.; Fang Z.; Velalopoulou A.; Kim J.; Thomas M.B.; Liu J.; Abramowitz R.G.; Kim Y.; Coskun A.F.; Krummel D.P.; Sengupta S.; MacDonald T.J.; Arvanitis C.; Single-cell analysis reveals effective siRNA delivery in brain tumors with microbubble-enhanced ultrasound and cationic nanoparticles. Sci Adv  2021,7(18),eabf7390","journal-title":"Sci Adv"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1006\/mcne.2000.0929","volume":"17","author":"K\u00fcgler S.","year":"2001","unstructured":"K\u00fcgler S.; Meyn L.; Holzm\u00fcller H.; Gerhardt E.; Isenmann S.; Schulz J.B.; B\u00e4hr M.; Neuron-specific expression of therapeutic proteins: evaluation of different cellular promoters in recombinant adenoviral vectors. Mol Cell Neurosci  2001,17(1),78-96","journal-title":"Mol Cell Neurosci"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ceca.2011.02.007","volume":"50","author":"Wayman G.A.","year":"2011","unstructured":"Wayman G.A.; Tokumitsu H.; Davare M.A.; Soderling T.R.; Analysis of CaM-kinase signaling in cells. Cell Calcium  2011,50(1),1-8","journal-title":"Cell Calcium"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fnmol.2016.00118","volume":"9","author":"Snow W.M.","year":"2016","unstructured":"Snow W.M.; Albensi B.C.; Neuronal gene targets of NF-\u03baB and their dysregulation in Alzheimer\u2019s disease. Front Mol Neurosci  2016,9,118","journal-title":"Front Mol Neurosci"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.2174\/13894501113146660213","volume":"14","author":"Aur\u00e9lie D.","year":"2013","unstructured":"Aur\u00e9lie D.; Carole E.; Nicole D.; Lentiviral vectors: a powerful tool to target astrocytes in vivo. Curr Drug Targets  2013,14(11),1336-1346","journal-title":"Curr Drug Targets"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1759091420981206","author":"Brenner M.","year":"2021","unstructured":"Brenner M.; Messing A.; Regulation of GFAP Expression. ASN Neuro  2021,13","journal-title":"ASN Neuro"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.addr.2009.05.002","volume":"61","author":"Grimm D.","year":"2009","unstructured":"Grimm D.; Small silencing RNAs: State-of-the-art. Adv Drug Deliv Rev  2009,61(9),672-703","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.nbd.2011.09.014","volume":"48","author":"Lentz T.B.","year":"2012","unstructured":"Lentz T.B.; Gray S.J.; Samulski R.J.; Viral vectors for gene delivery to the central nervous system. Neurobiol Dis  2012,48(2),179-188","journal-title":"Neurobiol Dis"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"Wang D.","year":"2019","unstructured":"Wang D.; Tai P.W.L.; Gao G.; Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov  2019,18(5),358-378","journal-title":"Nat Rev Drug Discov"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","volume":"20","author":"Terstappen G.C.","year":"2021","unstructured":"Terstappen G.C.; Meyer A.H.; Bell R.D.; Zhang W.; Strategies for delivering therapeutics across the blood\u2013brain barrier. Nat Rev Drug Discov  2021,20(5),362-383","journal-title":"Nat Rev Drug Discov"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"e3002112","DOI":"10.1371\/journal.pbio.3002112","volume":"21","author":"Huang Q.","year":"2023","unstructured":"Huang Q.; Chen A.T.; Chan K.Y.; Sorensen H.; Barry A.J.; Azari B.; Zheng Q.; Beddow T.; Zhao B.; Tobey I.G.; Moncada-Reid C.; Eid F.E.; Walkey C.J.; Ljungberg M.C.; Lagor W.R.; Heaney J.D.; Chan Y.A.; Deverman B.E.; Targeting AAV vectors to the central nervous system by engineering capsid\u2013receptor interactions that enable crossing of the blood\u2013brain barrier. PLoS Biol  2023,21(7),e3002112","journal-title":"PLoS Biol"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","volume":"25","author":"Goertsen D.","year":"2022","unstructured":"Goertsen D.; Flytzanis N.C.; Goeden N.; Chuapoco M.R.; Cummins A.; Chen Y.; Fan Y.; Zhang Q.; Sharma J.; Duan Y.; Wang L.; Feng G.; Chen Y.; Ip N.Y.; Pickel J.; Gradinaru V.; AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. Nat Neurosci  2022,25(1),106-115","journal-title":"Nat Neurosci"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41583-020-00382-z","volume":"21","author":"Nectow A.R.","year":"2020","unstructured":"Nectow A.R.; Nestler E.J.; Viral tools for neuroscience. Nat Rev Neurosci  2020,21(12),669-681","journal-title":"Nat Rev Neurosci"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3389\/fbioe.2020.00512","volume":"8","author":"Zheng Q.C.","year":"2020","unstructured":"Zheng Q.C.; Jiang S.; Wu Y.Z.; Shang D.; Zhang Y.; Hu S.B.; Cheng X.; Zhang C.; Sun P.; Gao Y.; Song Z.F.; Li M.; Dual-targeting nanoparticle-mediated gene therapy strategy for hepatocellular carcinoma by delivering small interfering RNA. Front Bioeng Biotechnol  2020,8,512","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2022.06.044","volume":"349","author":"Taghipour Y.D.","year":"2022","unstructured":"Taghipour Y.D.; Zarebkohan A.; Salehi R.; Rahimi F.; Torchilin V.P.; Hamblin M.R.; Seifalian A.; An update on dual targeting strategy for cancer treatment. J Control Release  2022,349,67-96","journal-title":"J Control Release"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11481-016-9724-3","volume":"12","author":"Joshi C.R.","year":"2017","unstructured":"Joshi C.R.; Labhasetwar V.; Ghorpade A.; Destination brain: the past, present, and future of therapeutic gene delivery. J Neuroimmune Pharmacol  2017,12(1),51-83","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"107870","DOI":"10.1016\/j.biotechadv.2021.107870","volume":"54","author":"Ch\u2019ng A.C.W.","year":"2022","unstructured":"Ch\u2019ng A.C.W.; Lam P.; Alassiri M.; Lim T.S.; Application of phage display for T-cell receptor discovery. Biotechnol Adv  2022,54,107870","journal-title":"Biotechnol Adv"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ymeth.2012.03.014","volume":"60","author":"Gera N.","year":"2013","unstructured":"Gera N.; Hussain M.; Rao B.M.; Protein selection using yeast surface display. Methods  2013,60(1),15-26","journal-title":"Methods"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ddr.20064","volume":"67","author":"Singh P.","year":"2006","unstructured":"Singh P.; Gonzalez M.J.; Manchester M.; Viruses and their uses in nanotechnology. Drug Dev Res  2006,67(1),23-41","journal-title":"Drug Dev Res"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.tibtech.2018.01.006","volume":"36","author":"Zheng M.","year":"2018","unstructured":"Zheng M.; Tao W.; Zou Y.; Farokhzad O.C.; Shi B.; Nanotechnology-based strategies for siRNA brain delivery for disease therapy. Trends Biotechnol  2018,36(5),562-575","journal-title":"Trends Biotechnol"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.addr.2016.08.004","volume":"110-111","author":"Tai W.","year":"2017","unstructured":"Tai W.; Gao X.; Functional peptides for siRNA delivery. Adv Drug Deliv Rev  2017,110-111,157-168","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.08570814","volume":"11","author":"Wiseman A.C.","year":"2016","unstructured":"Wiseman A.C.; Immunosuppressive Medications. Clin J Am Soc Nephrol  2016,11(2),332-343","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.biomaterials.2013.11.036","volume":"35","author":"Gower R.M.","year":"2014","unstructured":"Gower R.M.; Boehler R.M.; Azarin S.M.; Ricci C.F.; Leonard J.N.; Shea L.D.; Modulation of leukocyte infiltration and phenotype in microporous tissue engineering scaffolds via vector induced IL-10 expression. Biomaterials  2014,35(6),2024-2031","journal-title":"Biomaterials"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3389\/fbioe.2020.00627","volume":"8","author":"Sushnitha M.","year":"2020","unstructured":"Sushnitha M.; Evangelopoulos M.; Tasciotti E.; Taraballi F.; Cell membrane-based biomimetic nanoparticles and the immune system: immunomodulatory interactions to therapeutic applications. Front Bioeng Biotechnol  2020,8,627","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"e0226245","DOI":"10.1371\/journal.pone.0226245","volume":"14","author":"Elmer B.M.","year":"2019","unstructured":"Elmer B.M.; Swanson K.A.; Bangari D.S.; Piepenhagen P.A.; Roberts E.; Taksir T.; Guo L.; Obinu M.C.; Barneoud P.; Ryan S.; Zhang B.; Pradier L.; Yang Z.Y.; Nabel G.J.; Gene delivery of a modified antibody to A\u03b2 reduces progression of murine Alzheimer\u2019s disease. PLoS One  2019,14(12),e0226245","journal-title":"PLoS One"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.neurobiolaging.2016.04.020","volume":"44","author":"Zhao L.","year":"2016","unstructured":"Zhao L.; Gottesdiener A.J.; Parmar M.; Li M.; Kaminsky S.M.; Chiuchiolo M.J.; Sondhi D.; Sullivan P.M.; Holtzman D.M.; Crystal R.G.; Paul S.M.; Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer\u2019s disease mouse models. Neurobiol Aging  2016,44,159-172","journal-title":"Neurobiol Aging"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00429-020-02155-x","volume":"226","author":"S\u00e1nchez-Saras\u00faa S.","year":"2021","unstructured":"S\u00e1nchez-Saras\u00faa S.; Ribes-Navarro A.; Beltr\u00e1n-Bretones M.T.; S\u00e1nchez-P\u00e9rez A.M.; AAV delivery of shRNA against IRS1 in GABAergic neurons in rat hippocampus impairs spatial memory in females and male rats. Brain Struct Funct  2021,226(1),163-178","journal-title":"Brain Struct Funct"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/biology12020186","volume":"12","author":"Ghauri M.S.","year":"2023","unstructured":"Ghauri M.S.; Ou L.; AAV engineering for improving tropism to the central nervous system. Biology (Basel)  2023,12(2),186","journal-title":"Biology (Basel)"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1021\/ar2002232","volume":"45","author":"Wagner E.","year":"2012","unstructured":"Wagner E.; Polymers for siRNA delivery: inspired by viruses to be targeted, dynamic, and precise. Acc Chem Res  2012,45(7),1005-1013","journal-title":"Acc Chem Res"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.biopha.2015.02.015","volume":"71","author":"Nigatu A.S.","year":"2015","unstructured":"Nigatu A.S.; Vupputuri S.; Flynn N.; Ramsey J.D.; Effects of cell-penetrating peptides on transduction efficiency of PEGylated adenovirus. Biomed Pharmacother  2015,71,153-160","journal-title":"Biomed Pharmacother"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"2102145","DOI":"10.1002\/adhm.202102145","volume":"11","author":"Kavanagh E.W.","year":"2022","unstructured":"Kavanagh E.W.; Green J.J.; Toward gene transfer nanoparticles as therapeutics. Adv Healthc Mater  2022,11(7),2102145","journal-title":"Adv Healthc Mater"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3233\/JAD-2010-1220","volume":"19","author":"Markesbery W.R.","year":"2010","unstructured":"Markesbery W.R.; Neuropathologic alterations in mild cognitive impairment: a review. J Alzheimers Dis  2010,19(1),221-228","journal-title":"J Alzheimers Dis"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11910-017-0779-1","volume":"17","author":"Coughlin D.","year":"2017","unstructured":"Coughlin D.; Irwin D.J.; Emerging diagnostic and therapeutic strategies for tauopathies. Curr Neurol Neurosci Rep  2017,17(9),72","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"102575","DOI":"10.1016\/j.conb.2022.102575","volume":"75","author":"Mangalmurti A.","year":"2022","unstructured":"Mangalmurti A.; Lukens J.R.; How neurons die in Alzheimer\u2019s disease: Implications for neuroinflammation. Curr Opin Neurobiol  2022,75,102575","journal-title":"Curr Opin Neurobiol"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/biomedicines9050524","volume":"9","author":"Onyango I.G.","year":"2021","unstructured":"Onyango I.G.; Jauregui G.V.; \u010carn\u00e1 M.; Bennett J.P.; Stokin G.B.; Neuroinflammation in Alzheimer\u2019s disease. Biomedicines  2021,9(5),524","journal-title":"Biomedicines"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd4685","volume":"14","author":"Zuckerman J.E.","year":"2015","unstructured":"Zuckerman J.E.; Davis M.E.; Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov  2015,14(12),843-856","journal-title":"Nat Rev Drug Discov"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/alz.13703","volume":"20","author":"Ferguson C.M.","year":"2024","unstructured":"Ferguson C.M.; Hildebrand S.; Godinho B.M.D.C.; Buchwald J.; Echeverria D.; Coles A.; Grigorenko A.; Vangjeli L.; Sousa J.; McHugh N.; Hassler M.; Santarelli F.; Heneka M.T.; Rogaev E.; Khvorova A.; Silencing Apoe with divalent\u2010siRNAs improves amyloid burden and activates immune response pathways in Alzheimer\u2019s disease. Alzheimers Dement  2024,20(4),2632-2652","journal-title":"Alzheimers Dement"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.neuint.2017.07.007","volume":"112","author":"Kolli N.","year":"2018","unstructured":"Kolli N.; Lu M.; Maiti P.; Rossignol J.; Dunbar G.L.; Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases. Neurochem Int  2018,112,187-196","journal-title":"Neurochem Int"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40263-016-0405-9","volume":"31","author":"Patel M.M.","year":"2017","unstructured":"Patel M.M.; Patel B.M.; Crossing the blood\u2013brain barrier: recent advances in drug delivery to the brain. CNS Drugs  2017,31(2),109-133","journal-title":"CNS Drugs"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s40265-022-01717-z","volume":"82","author":"Rawal S.U.","year":"2022","unstructured":"Rawal S.U.; Patel B.M.; Patel M.M.; New drug delivery systems developed for brain targeting. Drugs  2022,82(7),749-792","journal-title":"Drugs"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/nm1117-1244","volume":"23","author":"Chakradhar S.","year":"2017","unstructured":"Chakradhar S.; Predictable response: Finding optimal drugs and doses using artificial intelligence. Nat Med  2017,23(11),1244-1247","journal-title":"Nat Med"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"100157","DOI":"10.1016\/j.hsr.2024.100157","volume":"11","author":"Martinelli D.D.","year":"2024","unstructured":"Martinelli D.D.; Machine learning for siRNA efficiency prediction: A systematic review. Heal Sci Rev  2024,11,100157","journal-title":"Heal Sci Rev"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","volume":"75","author":"Rafii M.S.","year":"2018","unstructured":"Rafii M.S.; Tuszynski M.H.; Thomas R.G.; Barba D.; Brewer J.B.; Rissman R.A.; Siffert J.; Aisen P.S.; Adeno-associated viral vector (serotype 2)\u2013nerve growth factor for patients with alzheimer disease: a randomized clinical trial. JAMA Neurol  2018,75(7),834-841","journal-title":"JAMA Neurol"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1001\/jamaneurol.2015.1807","volume":"72","author":"Tuszynski M.H.","year":"2015","unstructured":"Tuszynski M.H.; Yang J.H.; Barba D.; U H.S.; Bakay R.A.E.; Pay M.M.; Masliah E.; Conner J.M.; Kobalka P.; Roy S.; Nagahara A.H.; Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer disease. JAMA Neurol  2015,72(10),1139-1147","journal-title":"JAMA Neurol"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"e10258","DOI":"10.1002\/btm2.10258","volume":"7","author":"Zhao Z.","year":"2022","unstructured":"Zhao Z.; Anselmo A.C.; Mitragotri S.; Viral VECTOR\u2010BASED gene therapies in the clinic. Bioeng Transl Med  2022,7(1),e10258","journal-title":"Bioeng Transl Med"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/jnr.22830","volume":"90","author":"Iwasaki Y.","year":"2012","unstructured":"Iwasaki Y.; Negishi T.; Inoue M.; Tashiro T.; Tabira T.; Kimura N.; Sendai virus vector\u2010mediated brain\u2010derived neurotrophic factor expression ameliorates memory deficits and synaptic degeneration in a transgenic mouse model of Alzheimer\u2019s disease. J Neurosci Res  2012,90(5),981-989","journal-title":"J Neurosci Res"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/jnr.23564","volume":"93","author":"Li Y.","year":"2015","unstructured":"Li Y.; Wang J.; Zhang S.; Liu Z.; Neprilysin gene transfer: A promising therapeutic approach for Alzheimer\u2019s disease. J Neurosci Res  2015,93(9),1325-1329","journal-title":"J Neurosci Res"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010334094241112190337","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/238278\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010334094241112190337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:22:58Z","timestamp":1773256978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/238278\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":217,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892010334094241112190337","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}